Drug Negotiation Guidance Offers Additional Insight Into CMS’ Initial Offer Process

By Gabrielle Wanneh / March 16, 2023 at 1:54 PM
CMS will consider a drug’s clinical benefit to people in Medicare, the extent to which a drug meets an unmet medical need and a drug’s effect on specific populations compared to therapeutic alternatives when presenting drug companies with an initial negotiated price for the first 10 high-cost Part D drugs eligible for Medicare drug price negotiation, new program guidance released by HHS Wednesday (March 15) says. To determine negotiation-eligible drugs for the first round of negotiations, CMS will use data...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.